Severity COVID-19 | Treatment |
---|---|
Mild
| Continue 5-ASA, rectal therapies, budesonide Hold tofacitinib, methotrexate, and thiopurinesa Taper corticosteroids and/or switch to budesonide Delay biologics for 2 weeks or until COVID-19 resolvesa Individualize each patient: Weigh risks and benefits of COVID and IBD treatment. A patient with severe IBD may require treatment irrespective of COVID-19 |
Moderate
| Treat COVID-19 as per local guidelines Continue 5-ASA, rectal therapies, budesonide Hold tofacitinib, methotrexate, and thiopurinesa Taper corticosteroids and/or switch to budesonide Delay biologics for 2 weeks or until COVID-19 resolvesa |
Severe
| Treat COVID-19 as per local guidelines Continue 5-ASA, rectal therapies, budesonide Hold tofacitinib, methotrexate and thiopurinesa Taper corticosteroids and/or switch to budesonide Delay biologics for 2 weeks or until COVID-19 resolvesa |
aConsiderations for restarting therapy:
|
AGA = American Gastroenterological Association; ASA = aminosalicylates; IBD = inflammatory bowel disease; IOIBD = International Organization for the Study of Inflammatory Bowel Disease
Adapted from the AGA17 and IOIBD recommendations.18